The Cost-Effectiveness of Duloxetine in Chronic Low Back Pain: A US Private Payer Perspective-Author Response to Letter to the Editor
To the Editor-Thank you for allowing us to respond to the letter by Liedgens et al. regarding our cost-effectiveness analysis of duloxetine in chronic low back pain (CLBP) [1] . We are pleased to address their concerns. We do so by using the same numbering as in their letter.
Liedgens et al. question that study populations for opioid pain
trials may not be comparable to populations in trials for other treatments. In the review of the CLBP oral treatment trial literature for our meta-analysis, we found that trials, regardless of treatment, specified patient inclusion criteria of baseline and/ or flare pain scores of at least a 4 or 5 on a 0 to 10 scale, that is, at least moderate pain. The trials with the highest baseline pain scores were for etoricoxib [2, 3] We acknowledge that the dosing of tapentadol ER should have been lower. However, a revised analysis with lowered tapentadol ER dosing does not change the primary conclusion that duloxetine may be a cost-effective treatment for CLBP that dominates all strong opioids. The other issues raised by Liedgens et al. are plainly in error or not supported by the literature that was available at the time of the analysis. We stand by our research, analysis, and conclusions. Objectives: Depression is associated with reduced cognitive function and significant healthcare costs; however, the extent to which these two are related remains unclear. This study compared follow-up healthcare costs for major depressive disorder patients with and without cognitive dysfunction after antidepressant (AD) initiation. Methods: A large US health plan affiliated with OptumInsight was used to identify depressed patients with a newly prescribed AD who could be surveyed to assess cognitive function. Patients with neurological diseases associated with cognitive dysfunction were excluded. Patients were mailed a survey invitation and consent form. Patients maintained eligibility by confirming a depressive diagnosis and no excluding diagnoses. Consenting, eligible patients were interviewed by telephone and completed 4 cognitive function tests. Patients were classified as "cognitive normal (CN)" or "cognitive dysfunction (CD)" based on test scores relative to normative data. All-cause healthcare costs in the 3 months post-AD initiation were calculated from pharmacy and medical claims. T-tests compared 3-month costs of CN versus CD. Gamma models with log link compared healthcare costs between CD and CN patients, adjusting for race, sex, age, education, employment, depression severity, and comorbidities. Results: 13,537 patients were invited to participate in the study and 564 patients maintained eligibility and completed the study. Patients were mostly female (80%), mean age was 41 years, 98% had a high school degree or higher, and 84% were employed. A total of 45% (n¼255) met criteria for CD. Mean healthcare costs were $3,053 for all patients. Costs were $3,948 for the CD group compared to $2,312 for the CN (p ¼ 0.113). In the gamma models with costs as the outcome, CD patients had costs 1.46 times higher than CN patients (95% CI: 1.12, 1.92)(p¼0.0059). Conclusions: In this study population, healthcare costs were significantly higher in patients with cognitive dysfunction compared to those without cognitive dysfunction.
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